7.48
+0.12
(1.63%)
May 17 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 7.36 - 7.51 |
| 52 week | 5.38 - 10.86 |
| Open | 7.37 |
| Vol / Avg. | 15,860.00/11,367.00 |
| Mkt cap | 463.08M |
| P/E | - |
| Div/yield | - |
| EPS | -0.47 |
| Shares | 61.91M |
| Beta | 0.30 |
| Inst. own | - |
Events
Jun 3, 2013
Q2 2013 Nordion Inc. Earnings Release
Mar 6, 2013
Nordion Inc. Annual Shareholder Meeting
Mar 6, 2013
Q1 2013 Nordion Inc. Earnings Conference Call -
Mar 4, 2013
Q1 2013 Nordion Inc. Earnings Release
|
|
Key stats and ratios
| Q1 (Jan '13) | 2012 | |
| Net profit margin | -0.50% | -11.79% |
| Operating margin | -10.78% | 0.45% |
| EBITD margin | - | 25.79% |
| Return on average assets | -0.25% | -6.51% |
| Return on average equity | -0.55% | -12.04% |
| Employees | 500 | - |
| Carbon Disclosure Rating | - | - |
Address
447 March Rd.
OTTAWA, ON K2K 1X8
Canada
+1-613-5922790 (Phone)
+1-613-5926937 (Fax)
OTTAWA, ON K2K 1X8
Canada
+1-613-5922790 (Phone)
+1-613-5926937 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Nordion Inc. (Nordion)is a global health science company, engaged providing products and services used for the prevention, diagnosis and treatment of disease. The Company�s operations are organized into three business segments: Targeted Therapies, Sterilization Technologies and Medical Isotopes as well as certain corporate functions and activities reported as Corporate and Other. The Company�s Targeted Therapies segment is focused on the targeted treatment of cancer. The Company�s Medical Isotopes segment primarily focuses on products used in the diagnosis and treatment of diseases, including cardiac and neurological conditions, and several types of cancer. The Company�s shared corporate functions and activities are reported as Corporate and Other. The Company has two business units Targeted Therapies and Specialty Isotopes.
Officers and directors
| Steven M. West | President, Chief Executive Officer, Non-Independent Director | |
| G. Peter Dans | Chief Financial Officer | |
| Grant Gardiner | Senior Vice President, General Counsel, Corporate Secretary | |
| Christopher Ashwood | Senior Vice President - Corporate Services | |
| Jill Chitra | Senior Vice President - Quality and Regulatory Affairs | |
| Tamra Benjamin | Vice President - Public Affairs | |
| Tom Burnett | General Manager - Medical Isotopes | |
| Scott McIntosh | Chief Operating Officer - Specialty Isotopes | |
| William D. Anderson | Non-Executive Independent Chairman of the Board | |
| Jeffrey J. Brown | Independent Director |